Ophthalmic Surg Lasers Imaging Retina. 2020 Nov 1;51(11):658-667. doi: 10.3928/23258160-20201104-10.
Exploratory investigation of the effect of diabetic macular edema (DME) control with the 0.2 µg/day fluocinolone acetonide (FAc) intravitreal implant on quality of life (QOL) outcomes.
Post-hoc analysis of patients from the FAME study who received the FAc implant and had answered the National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ-25) at baseline and Year 3 (N = 324). Patients were divided into quartiles (area under the curve [AUC]-central subfield thickness [CST]/day; n = 81/quartile). NEIVFQ-25 and best-corrected visual acuity (BCVA) changes were analyzed per quartile during a period of 3 years.
NEI-VFQ-25 scores were significantly higher in patients with low AUC-CST/day (Quartiles 1 [P < .001] and 2 [P = .004]). Increases in NEIVFQ-25 subscale scores correlated with AUC-CST/day quartiles. BCVA significantly improved in patients with the lowest AUC-CST/day (Quartiles 1 and 2 [P < .001]).
There was a positive and sustained correlation between the long-term control of DME and patient-reported QOL outcomes for up to 3 years following a single FAc implant in patients with controlled DME. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:658-667.].
探索研究糖尿病性黄斑水肿（DME）控制后，0.2μg/天氟轻松醋酸酯（FAc）玻璃体内植入物对生活质量（QOL）的影响。
对 FAME 研究中接受 FAc 植入物且在基线和第 3 年（N=324）回答国家眼科研究所视觉功能问卷 25 项（NEI-VFQ-25）的患者进行了回顾性分析。患者分为四分位数（面积下的曲线[AUC]-中央视野厚度[CST]/天；n=81/四分位数）。分析了 3 年内每个四分位数的 NEIVFQ-25 和最佳矫正视力（BCVA）变化。
AUC-CST/天较低的患者的 NEI-VFQ-25 评分显著较高（四分位数 1[P<0.001]和 2[P=0.004]）。NEIVFQ-25 各分量评分的增加与 AUC-CST/天四分位数相关。BCVA 在 AUC-CST/天最低的患者中显著提高（四分位数 1 和 2[P<0.001]）。
在患有 DME 的患者中，单次 FAc 植入后长达 3 年，DME 的长期控制与患者报告的 QOL 结果之间存在正相关且持续相关。[眼科手术激光成像视网膜。2020;51:658-667.]。
